Embracing the Evolving Era of Pharmacotherapy in Obesity Management: Pharmacist Viewpoints on Unbiased, Data-Driven Treatment with Novel Agents (Podcast)

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an independent medical education grant from Novo Nordisk.

FACULTY

Jennifer N. Clements, PharmD, BCPS, BCACP, BC-ADM, CDCES, FCCP, FADCES
Clinical Professor and Director of Pharmacy Education
Department of Clinical Pharmacy and Outcomes Sciences
University of South Carolina College of Pharmacy
Greenville, SC 29605

FINANCIAL DISCLOSURE

Jennifer N. Clements, PharmD, BCPS, BCACP, BC-ADM, CDCES, FCCP, FADCES discloses the following: Speaker’s bureau - Eli Lilly and Novo Nordisk.

The clinical reviewer, Darrell Hulisz, RPh, PharmD has no relevant affiliations, no financial relationships or relationships to products or devices with a commercial interest related to the content of this activity to disclose.

Susanne Kwas, MSHF, BSN, RN, Robin Carrino and Alexia Hynes, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

All relevant financial relationships have been mitigated.

ACCREDITATION STATEMENTS

PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-24-101-H01-P
Credits: 0.5 hours (0.05 ceu)

Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee. This is a free continuing education activity.
Estimated time to complete activity: 30 minutes

Published

September 30, 2024

Expires

September 30, 2025

TARGET AUDIENCE

This activity has been designed to meet the educational needs of ambulatory care clinical pharmacists nationwide.

HOW TO EARN CREDIT

Participants must 1) read the learning objectives and faculty disclosures; 2) listen to the podcast in its entirety; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

GOAL

To equip ambulatory care clinical pharmacists with the knowledge, confidence, and tools they need to provide equitable, unbiased care for patients with overweight or obesity and interpolate novel anti-obesity medications into clinical practice on a patient-centric and evidence-driven basis, with emphasis on the evolving role of incretin analogues in the rapidly shifting treatment calculus.

EDUCATIONAL OBJECTIVES

After participating in this activity, learners will demonstrate the ability to:

• Discuss the obesity epidemic and ABCD complications
• Recognize the role of GLP1 receptor agonists in the multimodal management of obesity

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC or Novo Nordisk. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.